The Immune System and Chronic Heart Failure. Is the Heart in Control?

Journal of the American College of Cardiology

Volumn 53, Issue 12, 2009, Pages 1013-1020

  Fildes, James E ^a,b   Shaw, Steven M ^a   Yonan, Nizar ^a,b   Williams, Simon G ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

cytokines; heart failure; immune system; immunomodulation

Indexed keywords

CYTOKINE; ETANERCEPT; IMMUNOGLOBULIN G; INFLIXIMAB; PENTOXIFYLLINE; PLACEBO; TESTOSTERONE; THALIDOMIDE;

CARDIOTOXICITY; CLINICAL TRIAL; DEMOGRAPHY; DRUG MECHANISM; DRUG MEGADOSE; HEART EJECTION FRACTION; HEART FAILURE; HEART STRESS; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; MYOCARDIAL DISEASE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

HEART FAILURE; HUMANS; IMMUNOLOGIC FACTORS; MYOCARDIUM; STRESS, PHYSIOLOGICAL;

EID: 61949155082     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.11.046     Document Type: Review

References (57)

1. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
2. Mann D.L., and Young J.B. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 105 (1994) 897-904
3. Aukrust P., Ueland T., Lien E., et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83 (1999) 376-382
4. Fukunaga T., Soejima H., Irie A., et al. Relation between CD4+ T-cell activation and severity of chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 100 (2007) 483-488
5. Yndestad A., Holm A.M., Muller F., et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 60 (2003) 141-146
6. Vredevoe D.L., Widawski M., Fonarow G.C., et al. Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. Am J Cardiol 93 (2004) 1007-1011
7. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
8. Kurrelmeyer K.M., Michael L.H., Baumgarten G., et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A 97 (2000) 5456-5461
9. Monden Y., Kubota T., Inoue T., et al. Tumor necrosis factor-alpha is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. Am J Physiol Heart Circ Physiol 293 (2007) H743-H753
10. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
11. Davey P.P., and Ashrafian H. New therapies for heart failure: is thalidomide the answer?. QJM 93 (2000) 305-311
12. Moreira A.L., Sampaio E.P., Zmuidzinas A., et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177 (1993) 1675-1680
13. Agoston I., Dibbs Z.I., Wang F., et al. Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J Card Fail 8 (2002) 306-314
14. Gullestad L., Ueland T., Fjeld J.G., et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation 112 (2005) 3408-3414
15. Orea-Tejeda A., Arrieta-Rodriguez O., Castillo-Martinez L., et al. Effects of thalidomide treatment in heart failure patients. Cardiology 108 (2007) 237-242
16. Marriott J.B., Clarke I.A., Dredge K., et al. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 130 (2002) 75-84
17. Waage A., Sorensen M., and Stordal B. Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production. Lancet 335 (1990) 543
18. Sliwa K., Skudicky D., Candy G., et al. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 351 (1998) 1091-1093
19. Skudicky D., Sliwa K., Bergemann A., et al. Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline. Heart 84 (2000) 438-439
20. Bahrmann P., Hengst U.M., Richartz B.M., et al. Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms. Eur J Heart Fail 6 (2004) 195-201
21. Pugh P.J., Jones R.D., Jones T.H., et al. Heart failure as an inflammatory condition: potential role for androgens as immune modulators. Eur J Heart Fail 4 (2002) 673-680
22. Pugh P.J., Jones T.H., and Channer K.S. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 24 (2003) 909-915
23. Pugh P.J., Jones R.D., Malkin C.J., et al. Physiologic testosterone therapy has no effect on serum levels of tumour necrosis factor-alpha in men with chronic heart failure. Endocr Res 31 (2005) 271-283
24. Torre-Amione G., Anker S.D., Bourge R.C., et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 371 (2008) 228-236
25. Kajstura J., Cheng W., Reiss K., et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 74 (1996) 86-107
26. Takemura G., and Fujiwara H. Morphological aspects of apoptosis in heart diseases. J Cell Mol Med 10 (2006) 56-75
27. Boehme S.A., and Lenardo M.J. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur J Immunol 23 (1993) 1552-1560
28. Zheng L., Fisher G., Miller R.E., et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377 (1995) 348-351
29. Jones L.A., Chin L.T., Longo D.L., et al. Peripheral clonal elimination of functional T cells. Science 250 (1990) 1726-1729
30. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20 (2002) 395-425
31. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 12 (1994) 991-1045
32. Tang D., Kang R., Xiao W., et al. The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. J Immunol 179 (2007) 1236-1244
33. Gullestad L., Aass H., Fjeld J.G., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103 (2001) 220-225
34. Aukrust P., Gullestad L., Lappegard K.T., et al. Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. Circulation 104 (2001) 1494-1500
35. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 100 (1997) 151-157
36. Toga W., Tanonaka K., and Takeo S. Changes in Hsp60 level of the failing heart following acute myocardial infarction and the effect of long-term treatment with trandolapril. Biol Pharm Bull 30 (2007) 105-110
37. Lin L., Kim S.C., Wang Y., et al. HSP60 in heart failure: abnormal distribution and role in cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 293 (2007) H2238-H2247
38. Frantz S., Kobzik L., Kim Y.D., et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104 (1999) 271-280
39. Flohe S.B., Bruggemann J., Lendemans S., et al. Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype. J Immunol 170 (2003) 2340-2348
40. Grieve D.J., and Shah A.M. Oxidative stress in heart failure. More than just damage. Eur Heart J 24 (2003) 2161-2163
41. Tsutsui H. Oxidative stress in heart failure: the role of mitochondria. Intern Med 40 (2001) 1177-1182
42. Byrne J.A., Grieve D.J., Cave A.C., et al. Oxidative stress and heart failure. Arch Mal Coeur Vaiss 96 (2003) 214-221
43. Williamson C.L., Dabkowski E.R., Dillmann W.H., et al. Mitochondria protection from hypoxia/reoxygenation injury with mitochondria heat shock protein 70 overexpression. Am J Physiol Heart Circ Physiol 294 (2008) H249-H256
44. Lin K.M., Lin B., Lian I.Y., et al. Combined and individual mitochondrial HSP60 and HSP10 expression in cardiac myocytes protects mitochondrial function and prevents apoptotic cell deaths induced by simulated ischemia-reoxygenation. Circulation 103 (2001) 1787-1792
45. Saito K., Dai Y., and Ohtsuka K. Enhanced expression of heat shock proteins in gradually dying cells and their release from necrotically dead cells. Exp Cell Res 310 (2005) 229-236
46. Schild H., Arnold-Schild D., Lammert E., et al. Stress proteins and immunity mediated by cytotoxic T lymphocytes. Curr Opin Immunol 11 (1999) 109-113
47. Ramage J.M., Young J.L., Goodall J.C., et al. T cell responses to heat-shock protein 60: differential responses by CD4+ T cell subsets according to their expression of CD45 isotypes. J Immunol 162 (1999) 704-710
48. Asea A., Kraeft S.K., Kurt-Jones E.A., et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 6 (2000) 435-442
49. Damas J.K., Eiken H.G., Oie E., et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 47 (2000) 778-787
50. Athanassopoulos P., Vaessen L.M., Balk A.H., et al. Altered chemokine receptor profile on circulating leukocytes in human heart failure. Cell Biochem Biophys 44 (2006) 83-101
51. Zhou L., Azfer A., Niu J., et al. Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res 98 (2006) 1177-1185
52. Jaakkola K., Jalkanen S., Kaunismaki K., et al. Vascular adhesion protein-1, intercellular adhesion molecule-1 and P-selectin mediate leukocyte binding to ischemic heart in humans. J Am Coll Cardiol 36 (2000) 122-129
53. Wilhelmi M.H., Leyh R.G., Wilhelmi M., et al. Upregulation of endothelial adhesion molecules in hearts with congestive and ischemic cardiomyopathy: immunohistochemical evaluation of inflammatory endothelial cell activation. Eur J Cardiothorac Surg 27 (2005) 122-127
54. Andreassen A.K., Nordoy I., Simonsen S., et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 81 (1998) 604-608
55. Tsutamoto T., Hisanaga T., Fukai D., et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 76 (1995) 803-808
56. Yin W.H., Chen J.W., Young M.S., et al. Increased endothelial monocyte adhesiveness is related to clinical outcomes in chronic heart failure. Int J Cardiol 121 (2007) 276-283
57. Binah O., Shilkrut M., Yaniv G., et al. The Fas receptor-1,4,5-IP3 cascade: a potential target for treating heart failure and arrhythmias. Ann N Y Acad Sci 1015 (2004) 338-350